Scholar Rock Holding Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.8%projected annual EPS growth
Analyst Coverage
16analysts covering
FY Revenue (est.)
$5.8Mnext fiscal year
FY EPS (est.)
-$3.12next fiscal year
Monitoring Framework
Key Performance Indicators
Apitegromab BLA Approval Status QuarterlyTarget: FDA Approval
Cash, Cash Equivalents, and Marketable Securities Quarterly479.9MTarget: Maintain sufficient runway into 2027
Quarterly Net Loss Quarterly-105.5MTarget: Manage cash burn during launch preparation
Watch Items
- FDA PDUFA Action Date for ApitegromabTrigger: September 30, 2026Action: Monitor FDA decision and prepare for immediate commercial launch upon approval.
- Catalent Indiana Manufacturing Facility ClassificationTrigger: 90 days following reinspectionAction: Track FDA classification of the Catalent Indiana fill-finish facility to ensure supply chain readiness.
- Phase 2 FORGE Trial Initiation in FSHDTrigger: Mid-2026Action: Verify initiation of patient dosing and trial progress.
Research as of 19 Jun 2026